SERIES C CONVERTIBLE PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT VISTERRA, INC. June 29, 2016And Warrant Purchase Agreement • November 9th, 2016 • Visterra, Inc. • Pharmaceutical preparations • Delaware
This Series C Convertible Preferred Stock and Warrant Purchase Agreement dated as of June 29, 2016 (this “Agreement”) is made by and among (i) Visterra, Inc., a Delaware corporation (the “Company”), (ii) the persons and entities listed on Schedule 1 hereto (each individually, a “Purchaser” and collectively, the “Purchasers”), (iii) solely for the purposes of Sections 6 through 11 of this Agreement, the “Preferred Holders” (as defined in Section 8.1 below) who are not Purchasers, and, (iv) solely for the purposes of Sections 8 through 11 of this Agreement, the “Founder Holders” (as defined in Section 8.1 below), who are not Purchasers.
AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) u RATING PAGE OF PAGES 1 70 ASPR-BARDA 200 Independence Ave., S.W. Room. 640-G Washington DC 20201 ASPR-BARDA 330 Independence Ave., SW, Room. G644 Washington DC 20201 VISTERRA,...Contract Performance Report • November 9th, 2016 • Visterra, Inc. • Pharmaceutical preparations
This contract is for the advanced development of VIS410. Visterra, Inc. will develop a robust data package to support a BLA for the licensure of VIS410 as a treatment for severe/hospitalized influenza and patients at high risk of complications due to influenza infection. Options are also included for the treatment of pediatrics.
